4//SEC Filing
YANCOPOULOS GEORGE 4
Accession 0001226690-25-000005
CIK 0000872589other
Filed
Dec 10, 7:00 PM ET
Accepted
Dec 11, 4:27 PM ET
Size
13.1 KB
Accession
0001226690-25-000005
Insider Transaction Report
Form 4
YANCOPOULOS GEORGE
DirectorEVP CSO & Pres Regn Res Labs
Transactions
- Exercise/Conversion
Common Stock
2025-12-09$555.67/sh+146,815$81,580,691→ 442,334 total - Tax Payment
Common Stock
2025-12-09$701.51/sh−131,874$92,510,930→ 310,460 total - Exercise/Conversion
Non-Qualified Stock Option (right to buy)
2025-12-09−146,815→ 0 totalExercise: $555.67Exp: 2025-12-16→ Common Stock (146,815 underlying)
Holdings
- 71,487(indirect: By 2024 GRAT)
Common Stock
- 200,000(indirect: By 2025 GRAT)
Common Stock
- 5,962(indirect: By 401(k))
Common Stock
- 180,000(indirect: By Trust)
Common Stock
- 101,988(indirect: by 2024 GRAT II)
Common Stock
- 56,048(indirect: By Children)
Common Stock
Footnotes (2)
- [F1]As investment trustee of trusts for the benefit of the reporting person's children.
- [F2]The stock option award vested in four equal annual installments, commencing one year after the date of grant.
Documents
Issuer
REGENERON PHARMACEUTICALS, INC.
CIK 0000872589
Entity typeother
Related Parties
1- filerCIK 0001226690
Filing Metadata
- Form type
- 4
- Filed
- Dec 10, 7:00 PM ET
- Accepted
- Dec 11, 4:27 PM ET
- Size
- 13.1 KB